Announced that COVID-19 Vaccine Can Protect Children aged 5-11

As a result of studies conducted by Pfizer/BioNTech, it was announced that children between the ages of 5-11 are eligible for vaccination. The vaccinated children tolerated the vaccine well, but developed as many antibodies as do vaccinated people aged 16-25.

With the delta variant making children more vulnerable to COVID-19 than before, the debate over whether children should be vaccinated has ignited. Although the Delta variant is not new, a definite decision has not been taken yet; because experts and officials agreed that caution should be exercised on this issue. We do not know when official decisions will come, but statements have been made that this time may be close.

BioNTech’s co-founder Dr. Özlem Türeci had previously stated that the vaccine that can be administered to young children is no different from the current vaccine. In the company’s new statement, the Pfizer/BioNTech vaccine It is well tolerated in children aged 5-11 years. and induced strong immune response.

The vaccine had a positive effect on children:

The world has come a long way in vaccination studies against the COVID-19 virus. The vast majority of adults have been vaccinated and have taken the most effective precaution they can take. However, the delta variant, the most dangerous variant of the virus that has appeared so far, has been enough to worry us all again in recent months. It has been seen that the virus, which can have fatal consequences in young people, sometimes also targets children. Of course, they are of school age and high risk of transmission it was fine too. Therefore, evaluations began to protect children from the dangerous variant.

The American pharmaceutical company Pfizer, which co-produces the COVID-19 vaccines, and the German biotechnology company BioNTech, have concluded that the vaccine is well tolerated in people aged 5-11, as a result of ongoing research. In addition to not showing any adverse reactions, the vaccine created a strong immune response in children, making them more prone to all variants, including delta. The amount of antibodies that children in this age group get with the vaccine, It was the same as that of individuals aged 16-25.

RELATED NEWS

Concerned Statement About the Number of Positive Cases in Children After School Opening

Emphasizing that child COVID-19 cases have increased by 240% in the USA, Pfizer President Albert Bourla said, “Public health highlights the need for vaccination. Clinical trial results provide a strong basis for approval of our vaccine for children ages 5 to 11, and we plan to present these results to the FDA and other authorities immediately.” In his statements, he stated that he hopes the vaccine will be made available to children soon. Uğur Şahin, CEO of BioNTech, before the start of winter announced that the data obtained for school-age children has been transmitted to the competent authorities.

Source :
https://www.birgun.net/haber/biontech-pfizer-covid-19-asisi-5-11-yas-grubunda-koruyucu-359339


source site